Recent Advances across T cell-based Therapeutics

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across T cell-based therapeutics. Novel T cell receptor-based therapeutic platforms and robust T cell target discovery platforms are profiled. The corresponding clinical trials scenario is also depicted, along with industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapi

Table of Contents

Recent Advances across T cell-based TherapeuticsInnovations in T cell-based TherapiesNovel T cell Engager Platform for Targeting Malignant CellsUsing Dual-affinity Re-targeting for Cancer and Autoimmune DiseaseNovel T cell Receptor (TCR)-based Therapeutic Platform Robust T cell Target Discovery PlatformClinical Trial Analysis and Industry InteractionsSummary of Key T cell-based Therapeutics in Clinical StudiesSummary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.